DP4, characterized by TET2 and/or SRSF2 mutations, included a significant number of patients (n = 93) with MDS, MPN, and MDS/MPN that exhibited an adverse prognosis [25,26]. This evidence concerns the gene SRSF2 and myeloproliferative disorder.